The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Challenges and opportunities of drug repositioning
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
From patients to partners: participant-centric initiatives in biomedical research
Kaye, J., Curren, L., Anderson, N., Edwards, K., Fullerton, S. M., Kanellopoulou, N., Lund, D., MacArthur, D. G., Mascalzoni, D., Shepherd, J., et al. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3218 · Cited by 293
Rare diseases and orphan drugs
Melnikova, I. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3654 · Cited by 213
Drug repositioning: Re-investigating existing drugs for new therapeutic indications
Padhy, B., & Gupta, Y. (2011) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.81870 · Cited by 206
Thalidomide: A review of approved and investigational uses
Matthews, S. J., & McCoy, C. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80085-1 · Cited by 203
The value of drug repositioning in the current pharmaceutical market
Tobinick, E. L. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.2.1303818 · Cited by 193
ALKoma: A Cancer Subtype with a Shared Target
Mano, H. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0009 · Cited by 182
Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy
Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., Petersen, K. L., Rowbotham, M. C., & Campbell, J. N. (2012) · Pain · doi:10.1016/j.pain.2012.04.014 · Cited by 165
Cappelleri, J. C., Siegel, R. L., Osterloh, I. H., & Rosen, R. C. (2000) · Urology · doi:10.1016/s0090-4295(00)00697-x · Cited by 140
Shaw, A. T., Yasothan, U., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3600 · Cited by 140
Dissociation of periodic leg movements from arousals in restless legs syndrome
Manconi, M., Ferri, R., Zucconi, M., Bassetti, C. L., Fulda, S., Aricò, D., & Ferini‐Strambi, L. (2012) · Annals of Neurology · doi:10.1002/ana.23565 · Cited by 134
The value of drug repositioning in the current pharmaceutical market
Tobinick, E. L. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.2.1343228 · Cited by 133
Sinclair, A., Appel, G. B., Dooley, M. A., Ginzler, E. M., Isenberg, D. A., Jayne, D. R. W., Wofsy, D., & Solomons, N. (2007) · Lupus · doi:10.1177/0961203307084712 · Cited by 117
Dapoxetine: a new option in the medical management of premature ejaculation
McMahon, C. G. (2012) · Therapeutic Advances in Urology · doi:10.1177/1756287212453866 · Cited by 110
Glucocorticoid Receptor Antagonists
Clark, R. D. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608784535011 · Cited by 82
Khidhir, K. G., Woodward, D. F., Farjo, N. P., Farjo, B., Tang, E. S. ‐., Wang, J. W., Picksley, S. M., & Randall, V. A. (2012) · The FASEB Journal · doi:10.1096/fj.12-218156 · Cited by 69
Mycophenolate mofetil in the treatment of systemic lupus erythematosus
Dall’Era, M. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328349a1e5 · Cited by 57
DUROS® Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months
Rohloff, C. M., Alessi, T. R., Yang, B., Dahms, J., Carr, J. P., & Lautenbach, S. D. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200316 · Cited by 42
The CTSA Pharmaceutical Assets Portal – a public–private partnership model for drug repositioning
Marusina, K., Welsch, D. J., Rose, L. M., Brock, D., & Bahr, N. J. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.06.006 · Cited by 37
Lin, S., Sui, J., Cotard, S., Fung, B. P., Andersen, J., Zhu, P., Messadi, N. E., Lehár, J., Lee, M., & Staunton, J. E. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0313 · Cited by 22
Rickles, R. J., Tam, W. F., Giordano, T. P., Pierce, L. T., Farwell, M., McMillin, D. W., Necheva, A. S., CROWE, D. F., Chen, M., Avery, W., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0925 · Cited by 19
Cited by
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Deep-Learning-Based Drug–Target Interaction Prediction
Wen, M., Zhang, Z., Niu, S., Sha, H., Yang, R., Yun, Y., & Lu, H. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00618 · Cited by 576
Shaping the interaction landscape of bioactive molecules
Gfeller, D., Michielin, O., & Zoete, V. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt540 · Cited by 501
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Talevi, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00205 · Cited by 381
Metadata
- Authors
- Novac, N.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 34
- Issue
- 5
- Pages
- 267-272
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W1968217711
- Cited by
- 374
- References
- 25
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.